Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
BACKGROUND: Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer (PCa) may improve survival rates. OBJECTIVE: To determine outcomes for men diagnosed with advanced PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT random...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2016
|
| _version_ | 1797106156212060160 |
|---|---|
| author | Johnston, T Shaw, G Lamb, A Parashar, D Greenberg, D Xiong, T Edwards, A Gnanapragasam, V Holding, P Herbert, P Davis, M Mizielinsk, E Lane, J Oxley, J Robinson, M Mason, M Staffurth, J Bollina, P Catto, J Doble, A Doherty, A Gillatt, D Kockelbergh, R Kynaston, H Prescott, S Paul, A Powell, P Rosario, D Rowe, E Donovan, J Hamdy, F Neal, D ProtecT study group |
| author_facet | Johnston, T Shaw, G Lamb, A Parashar, D Greenberg, D Xiong, T Edwards, A Gnanapragasam, V Holding, P Herbert, P Davis, M Mizielinsk, E Lane, J Oxley, J Robinson, M Mason, M Staffurth, J Bollina, P Catto, J Doble, A Doherty, A Gillatt, D Kockelbergh, R Kynaston, H Prescott, S Paul, A Powell, P Rosario, D Rowe, E Donovan, J Hamdy, F Neal, D ProtecT study group |
| author_sort | Johnston, T |
| collection | OXFORD |
| description | BACKGROUND: Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer (PCa) may improve survival rates. OBJECTIVE: To determine outcomes for men diagnosed with advanced PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT randomised trial. DESIGN, SETTING, AND PARTICIPANTS: Mortality was compared for 492 men followed up for a median of 7.4 yr to a contemporaneous cohort of men from the UK Anglia Cancer Network (ACN) and with a matched subset from the ACN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PCa-specific and all-cause mortality were compared using Kaplan-Meier analysis and Cox's proportional hazards regression. RESULTS AND LIMITATIONS: Of the 492 men excluded from the ProtecT cohort, 37 (8%) had metastases (N1, M0=5, M1=32) and 305 had locally advanced disease (62%). The median PSA was 17μg/l. Treatments included radical prostatectomy (RP; n=54; 11%), radiotherapy (RT; n=245; 50%), androgen deprivation therapy (ADT; n=122; 25%), other treatments (n=11; 2%), and unknown (n=60; 12%). There were 49 PCa-specific deaths (10%), of whom 14 men had received radical treatment (5%); and 129 all-cause deaths (26%). In matched ProtecT and ACN cohorts, 37 (9%) and 64 (16%), respectively, died of PCa, while 89 (22%) and 103 (26%) died of all causes. ProtecT men had a 45% lower risk of death from PCa compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38-0.83; p=0.0037), but mortality was similar in those treated radically. The nonrandomised design is a limitation. CONCLUSIONS: Men with PSA-detected advanced PCa excluded from ProtecT and treated radically had low rates of PCa death at 7.4-yr follow-up. Among men who underwent nonradical treatment, the ProtecT group had a lower rate of PCa death. Early detection through PSA testing, leadtime bias, and group heterogeneity are possible factors in this finding. PATIENT SUMMARY: Prostate cancer that has spread outside the prostate gland without causing symptoms can be detected via prostate-specific antigen testing and treated, leading to low rates of death from this disease. |
| first_indexed | 2024-03-07T06:57:43Z |
| format | Journal article |
| id | oxford-uuid:feb2cc6f-86e4-4af1-b7c1-a28815ccfae1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:57:43Z |
| publishDate | 2016 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:feb2cc6f-86e4-4af1-b7c1-a28815ccfae12022-03-27T13:38:48ZMortality among nen with advanced prostate cancer excluded from the ProtecT TrialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:feb2cc6f-86e4-4af1-b7c1-a28815ccfae1EnglishSymplectic Elements at OxfordElsevier2016Johnston, TShaw, GLamb, AParashar, DGreenberg, DXiong, TEdwards, AGnanapragasam, VHolding, PHerbert, PDavis, MMizielinsk, ELane, JOxley, JRobinson, MMason, MStaffurth, JBollina, PCatto, JDoble, ADoherty, AGillatt, DKockelbergh, RKynaston, HPrescott, SPaul, APowell, PRosario, DRowe, EDonovan, JHamdy, FNeal, DProtecT study groupBACKGROUND: Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer (PCa) may improve survival rates. OBJECTIVE: To determine outcomes for men diagnosed with advanced PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT randomised trial. DESIGN, SETTING, AND PARTICIPANTS: Mortality was compared for 492 men followed up for a median of 7.4 yr to a contemporaneous cohort of men from the UK Anglia Cancer Network (ACN) and with a matched subset from the ACN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PCa-specific and all-cause mortality were compared using Kaplan-Meier analysis and Cox's proportional hazards regression. RESULTS AND LIMITATIONS: Of the 492 men excluded from the ProtecT cohort, 37 (8%) had metastases (N1, M0=5, M1=32) and 305 had locally advanced disease (62%). The median PSA was 17μg/l. Treatments included radical prostatectomy (RP; n=54; 11%), radiotherapy (RT; n=245; 50%), androgen deprivation therapy (ADT; n=122; 25%), other treatments (n=11; 2%), and unknown (n=60; 12%). There were 49 PCa-specific deaths (10%), of whom 14 men had received radical treatment (5%); and 129 all-cause deaths (26%). In matched ProtecT and ACN cohorts, 37 (9%) and 64 (16%), respectively, died of PCa, while 89 (22%) and 103 (26%) died of all causes. ProtecT men had a 45% lower risk of death from PCa compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38-0.83; p=0.0037), but mortality was similar in those treated radically. The nonrandomised design is a limitation. CONCLUSIONS: Men with PSA-detected advanced PCa excluded from ProtecT and treated radically had low rates of PCa death at 7.4-yr follow-up. Among men who underwent nonradical treatment, the ProtecT group had a lower rate of PCa death. Early detection through PSA testing, leadtime bias, and group heterogeneity are possible factors in this finding. PATIENT SUMMARY: Prostate cancer that has spread outside the prostate gland without causing symptoms can be detected via prostate-specific antigen testing and treated, leading to low rates of death from this disease. |
| spellingShingle | Johnston, T Shaw, G Lamb, A Parashar, D Greenberg, D Xiong, T Edwards, A Gnanapragasam, V Holding, P Herbert, P Davis, M Mizielinsk, E Lane, J Oxley, J Robinson, M Mason, M Staffurth, J Bollina, P Catto, J Doble, A Doherty, A Gillatt, D Kockelbergh, R Kynaston, H Prescott, S Paul, A Powell, P Rosario, D Rowe, E Donovan, J Hamdy, F Neal, D ProtecT study group Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial |
| title | Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial |
| title_full | Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial |
| title_fullStr | Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial |
| title_full_unstemmed | Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial |
| title_short | Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial |
| title_sort | mortality among nen with advanced prostate cancer excluded from the protect trial |
| work_keys_str_mv | AT johnstont mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT shawg mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT lamba mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT parashard mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT greenbergd mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT xiongt mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT edwardsa mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT gnanapragasamv mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT holdingp mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT herbertp mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT davism mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT mizielinske mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT lanej mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT oxleyj mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT robinsonm mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT masonm mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT staffurthj mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT bollinap mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT cattoj mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT doblea mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT dohertya mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT gillattd mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT kockelberghr mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT kynastonh mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT prescotts mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT paula mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT powellp mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT rosariod mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT rowee mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT donovanj mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT hamdyf mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT neald mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial AT protectstudygroup mortalityamongnenwithadvancedprostatecancerexcludedfromtheprotecttrial |